Kuan-Lang Lai

PI-88, a novel heparanase inhibitor, as adjuvant therapy for hepatocellular carcinoma: A large randomized phase II clinical trial

L. Jeng, Pei-Jer Chen, Chun-Jen Liu, 2007 .

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.

L. Jeng, M. Ho, Pei-Jer Chen, 2009, Journal of hepatology.

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.

L. Jeng, M. Ho, Pei-Jer Chen, 2014, World journal of gastroenterology.

The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.

Shan-Chwen Chang, Hsiang-Chi Lee, Ting-Wan Lin, 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

624PDA phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection

L. Jeng, M. Ho, Y. Mao, 2017 .